We are 1-[3-(2-aminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide CAS:88919-22-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  1-[3-(2-aminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide
CAS.NO:  88919-22-6
Didesmethyl sumatriptan
3-(2-aminoethyl)-1H-indole-5-yl-N-methyl methane sulphonamide

Molecular Formula: C12H17N3O2S
Molecular Weight:  267.34700

Physical and Chemical Properties:
Density: 1.394g / cm3
Boiling point: 523.772ºC at 760 mmHg
Melting point: 151-154ºC
Flash point: 270.568ºC
Refractive index: 1.65

Appearance:Beige powder

 25kg  cardboard drum or according to customer specified requirements
Storage: Refrigerator.Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Intermediates of Sumatriptan succinate CAS:103628-48-4
Intermediates of Sumatriptan CAS:103628-46-2


Related News: “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”N-isobutil-3-nitroquinolin-4-amina CAS:99009-85-5 Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.cis-11-Eicosenoic acid China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.207226-02-6 Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API.An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.

Related Products
Product Name
3-boc-amino-2,6-dioxopiperidine View Details
(4-(9H-Carbazol-9-yl)phenyl)boronic acid View Details
2-phenoxy-1-phenylethanol Cas:4249-72-3 View Details
4-Methyl-N3-[4-(3-Pyridinyl)-2-Pyrimidinyl]-1,3-Benzenediamine manufacturer 4-iodo-1-butanol manufacturer Cobalt oxide manufacturer 2,3-Dimethyl-2H-indazol-6-amine manufacturer 2-Chloro-5-nitrobenzenesulfonic acid manufacturer